Formation; Purpose. Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or “JSC”) for the overall coordination and oversight of the Parties’ activities under this Agreement. The role of the JSC shall be:
Formation; Purpose. 8 3.1.2 Membership.............................................................................8 3.1.3 Meetings...............................................................................9 3.1.4 Chairpersons...........................................................................9 3.1.5 Decision-Making........................................................................9 3.1.6 Dispute Resolution.....................................................................9
Formation; Purpose. Within ten (10) days after the Effective Date, AeroGen and Pathogenesis shall establish the Joint Development Team ("JDT"). The general purposes of the JDT shall be (i) to determine the overall technical strategy for the development of the Inhaler and Adapter (and the way in which they coact or interfit with the Ampoule), (ii) to oversee and coordinate the parties' activities in the development of the Inhaler and Adapter pursuant to the specifications and the timelines set forth in Exhibits A and B, and (iii) to develop and propose for the parties' approval the final specifications for the Inhaler and Adapter, all based on the principles of prompt and diligent development, consistent with good pharmaceutical and medical device practices. The JDT shall perform such other functions as appropriate to further the purposes of the this Agreement as determined by the parties, including the periodic evaluation of performance against goals.
Formation; Purpose. Within thirty (30) days of the Effective Date, the Parties will establish a Joint Steering Committee (the “Joint Steering Committee” or “JSC”), which (i) shall oversee, coordinate and review recommendations and approve decisions for the Development, Regulatory Approval, Manufacture and Commercialization of Product to Physician Targets for use in the Field in the Territory. The JSC shall coordinate the co-promotion of Product by the Parties and all budgets for such activities in the Field in the Territory. Within ten (10) Business Days of the Effective Date, each of MAP and ALLERGAN shall designate an individual who shall initially serve as a co-chair for the JSC. The JSC shall have the authority to set up joint teams, committees and subcommittees as necessary to Commercialize Product.
Formation; Purpose. Within [***] ([***]) days of the Effective Date, Pieris and AstraZeneca shall each appoint two (2) members each to a joint development committee (the “JDC”). The JDC shall be a subcommittee of the JSC and shall be responsible for implementing the Lead Product Development Plans and Collaboration Product Development Plan subject to the terms and conditions of this Agreement.
Formation; Purpose. (a) The formation of the Company, a single employer separate and apart from any other entity, without limitation, as a Delaware limited liability company under the Delaware Limited Liability Company Act of 1992, as amended (the “Act”), and all actions taken by the Person who executed and filed its certificate of formation are hereby adopted and ratified, such Person being an “authorized person” within the meaning of the Act.
Formation; Purpose. Within [***] ([***]) days of the Effective Date, Pieris and AstraZeneca shall each appoint three (3) members each to the joint steering committee (the “JSC”). The JSC shall be responsible for managing the overall collaboration between the Parties and AstraZeneca and resolving any disputed matters that may arise in any subcommittee(s) created by the JSC. Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Formation; Purpose. The Company was formed on October 19, 2004 pursuant to the Law under the name "DCI Management, LLC". The business office of the Company shall be at such other place or places as the Members may from time to time designate. The sole and exclusive purpose of the Company shall be to be the manager of DCI and its interests, including without limitation, Gavella Corp., pursuant to the terms and provisions of this Agreement.
Formation; Purpose. The Company has been organized as a Delaware limited liability company by the filing of Certificate of Formation pursuant to the Act, with the Secretary of State of Delaware on September 2, 2008. The Company was formed for the purpose of transacting any lawful business for which limited liability companies may be organized under the laws of the State of Delaware. Except as expressly provided herein to the contrary, all activities of the Company shall be governed by the Act.
Formation; Purpose. (a) The Company was formed by the filing of a Certificate of Formation with the Secretary of State of the State of Delaware on March 31, 2007 pursuant to and in accordance with the Delaware Limited Liability Company Act of 1992, as amended (the "Act").
